Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization

被引:0
作者
Yanyan Koenig
Felix Bock
Folkert Horn
Friedrich Kruse
Katja Straub
Claus Cursiefen
机构
[1] Friedrich-Alexander University Erlangen-Nürnberg,Department of Ophthalmology
[2] Friedrich-Alexander University Erlangen-Nürnberg,University Pharmacy
来源
Graefe's Archive for Clinical and Experimental Ophthalmology | 2009年 / 247卷
关键词
Cornea; Angiogeneis; Inhibition; Safety; Bevacizumab; Eye drops;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1375 / 1382
页数:7
相关论文
共 70 条
[1]  
Chang JH(2001)Corneal neovascularization Curr Opin Ophthalmol 12 242-249
[2]  
Gabison EE(2007)Inhibition of angiogenesis in the anterior chamber of the eye Ophthalmologe 104 336-344
[3]  
Kato T(2006)Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision Proc Natl Acad Sci U S A 103 11405-11410
[4]  
Azar DT(2000)Angiogenesis in cancer and other diseases Nature 407 249-257
[5]  
Bock F(1994)Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 1480-1487
[6]  
Koenig Y(2007)Safety profile of Bevacizumab on cultured human corneal cells Cornea 26 977-982
[7]  
Dietrich T(2008)Bevacizumab (Avastin) eye drops inhibit corneal neovascularization Graefes Arch Clin Exp Ophthalmol 246 281-284
[8]  
Zimmermann P(2008)The effect of topical Bevacizumab on corneal neovascularization Ophthalmology 115 e33-e38
[9]  
Baier M(2000)Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas Invest Ophthalmol Vis Sci 41 2514-2522
[10]  
Cursiefen C(2000)Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization Cornea 19 526-533